+ Watch LXRX
on My Watchlist
A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.
If there's one thing recent history has told us about Lexicon, it's that a market cap of over a billion for their highly speculative pipeline will not hold. Lexicon has assets, to be sure, and at a market cap of 500 or even 600M in this frothy market you wouldn't be hearing anything about them from me. But LX4211 doesn't have a clear place in the rapidly evolving field of glycemic control, and progression to phase III is on hold as a partnership is awaited. Telotristat is in the early stages of what undoubtedly will be a long phase III trial for the narrow indication of carcinoid. If the last year's pattern holds, the share price will be well under 2 again before any positive catalysts emerge from the pipeline.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions